MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2.01Results of Operations and Financial Condition
Item 7.01Regulation FD
On February 20, 2018, MiMedx Group, Inc. (the “Company”) announced that it will postpone the release of its financial results, as well as the filing of its Form 10-K, for the year ended December 31, 2017, as well as certain other matters.A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.The information provided to Item 2.02 and Item 7.01 of this Form 8-K is to be considered “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
MIMEDX GROUP, INC. ExhibitEX-99.1 2 a8-kexhibit9912202018x01.htm PRESS RELEASE Exhibit Exhibit 99.1MiMedx Postpones Release of its Fourth Quarter and Fiscal Year 2017 Financial ResultsMarietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
